Clear Search

Showing 2 results for “Otawa S”.

Efficacité du traitement à long terme avec le baricitinib 2 mg en prise unique quotidienne chez les patients atteints de polyarthrite rhumatoïde active : Analyse post-hoc de deux études de phase III randomisées et contrôlées de 24 semaines et d'une étude en extension à long terme

Wells AF, et al. Rheumatol Ther. 2021. Epub ahead of print. DOI: 10.1007/s40744-021-00317-9.

Analysis by Wells, et al. demonstrates long-term efficacy and tolerability of baricitinib 2 mg daily for up to 120 weeks in patients with rheumatoid arthritis.Using data from two completed phase III studies, RA-BEAM (csDMARD-IR patients) and RA-BEACON (TNFi-IR patients), and one ongoing long-term extension study (RA-BEYOND), results demonstrated that the long-term maintenance of clinically relevant treatment goals, including LDA, remission and normative physical function, is achievable with bari...

Lire la Suite…

Diminution de la dose de Baricitinib chez les patients atteints de polyarthrite rhumatoïde avec un contrôle durable de la maladie: résultats d'une étude prospective

Ann Rheum Dis. 2019 Feb;78(2):171-178. DOI 10.1136/annrheumdis-2018-213271

In active RA patients, with an inadequate response (IR) to DMARDs who achieve low disease activity (LDA) following baricitinib (BARI) 4 mg treatment, disease control is better maintained with continued BARI 4 mg compared to tapering to 2 mg.The objective of this study was to investigate the effect of BARI tapering in patients achieving sustained disease control with BARI 4 mg.In the long-term extension study RA-BEYOND, patients receiving BARI 4 mg who achieved sustained LDA or remission at two c...

Lire la Suite…